Key result
Fibrinolytic agents, including tenecteplase and alteplase, are used for thrombolysis in acute ST-elevation myocardial infarction, pulmonary embolism, and ischaemic stroke.
This review provides a comprehensive overview of the pharmacology, indications, and prescribing information for commonly used fibrinolytic agents in conditions such as acute ST-elevation myocardial infarction, pulmonary embolism, and ischemic stroke.
Answers are grounded in this paper and cite their sources.
Reinforces standard thrombolytic indications across STEMI, PE, and stroke; extends RCT evidence to nurse prescribing models.
Fibrinolytic (thrombolytic) agents are used thrombolysis (clot breakdown) in several indications, including acute ST-elevation myocardial infarction, acute pulmonary embolism and acute ischaemic stroke. The pathophysiology of each condition is discussed, as well as indications for the use of fibrinolytic agents. The pathophysiology of thrombosis and the coagulation cascade—which comprises an extrinsic and an intrinsic pathway, leading to a common pathway—are outlined. Commonly used fibrinolytic agents include tenecteplase, reteplase, alteplase, streptokinase and urokinase. Each fibrinolytic agent is reviewed, including indications for use, mode of action, method of administration and dosage, side-effects and contraindications. This enables the reader to be well-informed about fibrinolytic agents and their uses, and provides up-to-date information on their prescription.
No takes yet. Share an insight, caveat, or question.
Katherine Potts (2011) conducted a review in Acute ST-elevation myocardial infarction, acute pulmonary embolism, and acute ischaemic stroke. Fibrinolytic agents (tenecteplase, reteplase, alteplase, streptokinase, urokinase) was evaluated. Fibrinolytic agents, including tenecteplase and alteplase, are used for thrombolysis in acute ST-elevation myocardial infarction, pulmonary embolism, and ischaemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: